This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Riluzole in Fragile X Syndrome

This study has been completed.
Sponsor:
Collaborator:
Indiana Clinical and Translational Sciences Institute
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT00895752
First received: May 6, 2009
Last updated: March 7, 2017
Last verified: March 2017
  Purpose
The purpose of this study is to investigate the effectiveness and tolerability of riluzole in adults with Fragile X Syndrome.

Condition Intervention Phase
Fragile X Syndrome Drug: Riluzole Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay

Resource links provided by NLM:


Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Clinical Global Impression-Improvement (CGI-I) [ Time Frame: Obtained at Week 6 ]
    The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse

  • Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) [ Time Frame: Obtained at Baseline and Week 6 ]
    The CY-BOCS PDD has been utilized in a largescale clinical treatment study of repetitive behavior in idiopathic ASDs. CYBOCS-PDD scores range from 0 to 20 and measure repetitive/compulsive behavior and not obsessions. Higher score indicate worse outcome.


Secondary Outcome Measures:
  • Aberrant Behavior Checklist [ Time Frame: Week 6 ]
    The Aberrant Behavior Checklist (ABC) is a 58-item measure of maladaptive behaviors and is used as a measure of drug effects. The ABC has 5 subscales: Social Withdrawal (16 items) ranging from 0 (not at all) to 48 (severe), Irritability (15 items) ranging from 0 (not at all) to 45 (severe), Inappropriate Speech (4 items) ranging from 0 (not at all) to 12 (severe), Hyperactivity (16 items) ranging from 0 (not at all) to 48 (severe), and Stereotypy (7 items) ranging from 0 (not at all) to 21 (severe). Items are rated from 0 (not at all) to 3 (severe).

  • The ADHD Rating Scale [ Time Frame: Week 6 ]
    The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity

  • The Clinical Global Impression - Severity Scale [ Time Frame: Week 6 ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill

  • The Peabody Picture Vocabulary Test [ Time Frame: Week 6 ]
    The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank.

  • The Social Reciprocity Scale [ Time Frame: Week 6 ]
    The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment.

  • Extra-cellular Signal-relatedness Kinase (ERK) [ Time Frame: Screen and Week 6 ]
    ERK activations times, as defined as the time in minutes for ERK phosphorylation to reach the half maximal level.


Enrollment: 6
Study Start Date: April 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Riluzole
Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
Drug: Riluzole
Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.

Detailed Description:

Fragile X Syndrome (FXS) represents the most common inherited form of intellectual disability. FXS is more common in males and the symptoms associated with the disorder are more marked in males. FXS is associated with characteristic physical features, behaviors, and comorbidities. Those with FXS often suffer from behavioral difficulties that include anxiety-related symptoms (shyness, social phobia, obsessive-compulsive disorder (OCD) symptoms), attention deficit hyperactivity symptoms (overarousal, hyperactivity, distractibility, impulsivity) and aggressive/self-injurious behaviors.

Riluzole is approved by the FDA for use in treating amyotrophic lateral sclerosis (ALS) in adults. Recently, riluzole has been the subject of several open-label studies describing the use of the drug in treatment-resistant depression and OCD.

Given the overlap between repetitive behavior in FXS and symptoms of OCD, it is logical to study riluzole in FXS given the compound's promise in ameliorating treatment-refractory symptoms of OCD.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females age 18 years or older.
  • Confirmed molecular diagnosis of Fragile X Syndrome.
  • Clinical Global Impression Severity (CGI-S) score of 3 or greater.
  • Significant interfering repetitive behavior as determined by the principal investigator.
  • Must be in good health as determined by screening procedures including a detailed medical history, and complete physical and neurological examination.
  • Dosing of concomitant medications during the study must remain stable.

Exclusion Criteria:

  • Pregnancy.
  • Concomitant use of another glutamatergic agent (memantine, topiramate, amantadine, among others.
  • Evidence of prior trial of riluzole and/or hypersensitivity/allergic reaction to riluzole.
  • Abnormal baseline liver function tests at screen or by history; or complete blood count abnormalities at screen or by history.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00895752

Locations
United States, Indiana
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
Indiana Clinical and Translational Sciences Institute
Investigators
Principal Investigator: Craig A. Erickson, MD Indiana University School of Medicine
  More Information

Publications:
Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT00895752     History of Changes
Other Study ID Numbers: 0809-11
Study First Received: May 6, 2009
Results First Received: July 29, 2015
Last Updated: March 7, 2017

Additional relevant MeSH terms:
Fragile X Syndrome
Syndrome
Disease
Pathologic Processes
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System
Riluzole
Anticonvulsants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents

ClinicalTrials.gov processed this record on September 21, 2017